Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Oct;132(5):789-809.
doi: 10.1002/jso.70075. Epub 2025 Sep 17.

Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers

Ada I Ozcan  1 , Arianexys Aquino López  1   2 , Mary K McKenna  1   3   4 , Malcolm K Brenner  1   4 , Alastair M Thompson  5
Affiliations
Review

Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers

Ada I Ozcan et al. J Surg Oncol. 2025 Oct.

Abstract

Peritoneal malignancy often indicates disruptions in multiple physiological systems resulting from widespread cancer. The heterogenous origin and dynamic nature of peritoneal cancer make it difficult to treat with standard approaches that fit into guidelines. We describe how successful treatment should address the underlying pathology, the systemic response to surgical treatments and target the immune perturbations that facilitate the establishment and propagation of this multifaceted disease.

Keywords: immunotherapy; peritoneal cancer; peritoneum; peri‐operative immunity; surgery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of Reviewed Immunotherapy Modalities.
Figure 2
Figure 2
Adoptive Cell Therapies for Peritoneal Cancer.
See this image and copyright information in PMC

References

    1. Baydoun M., Boidin L., Leroux B., et al., “Folate Receptor Targeted Photodynamic Therapy: A Novel Way to Stimulate Anti‐Tumor Immune Response in Intraperitoneal Ovarian Cancer,” International Journal of Molecular Sciences 24, no. 14 (2023): 11288. - PMC - PubMed
    1. Bakos O., Lawson C., Rouleau S., and Tai L. H., “Combining Surgery and Immunotherapy: Turning an Immunosuppressive Effect Into a Therapeutic Opportunity,” Journal for Immunotherapy of Cancer 6, no. 1 (2018): 86. - PMC - PubMed
    1. Waldman A. D., Fritz J. M., and Lenardo M. J., “A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice,” Nature Reviews Immunology 20, no. 11 (2020): 651–668. - PMC - PubMed
    1. Weiner L. M., Surana R., and Wang S., “Monoclonal Antibodies: Versatile Platforms for Cancer Immunotherapy,” Nature Reviews Immunology 10 (2010): 317–327. - PMC - PubMed
    1. Lin M. J., Svensson‐Arvelund J., Lubitz G. S., et al., “Cancer Vaccines: The Next Immunotherapy Frontier,” Nature Cancer 3 (2022): 911–926. - PubMed

MeSH terms